People that use Acomplia Rimonabant must be more carreful and pay attention to a problem that producer Sanofi-Aventis is now facing : If people don’t want to gain back the weight they lost on Acomplia, people are obligated to take this medication every day for the rest of their life.
In the Phase III clinical trials for Acomplia Rimonabant, people who were on rimonabant for a year lost up to 10 percent of their body weight. But while those who continued on Acomplia for a second year maintained their weight loss, those switched to a placebo tended to quickly regain the weight.
That could only suggest that if you want to keep weight lost while taking Acomplia Rimonabant from returning, people must take rimonabant indefinitely — a point the FDA advisory panel picked up on in majority and in conclusion that not enough long-term safety data had been submitted by producer Sanofi.
The FDA advisory panel declared in the minutes of the reunion that :”There was general agreement among the committee that there needs to be more long-term data; the concern being that of having limited 2-year study data being used to assess a medication that is going to be used for a longterm,”
Cluzel said “With any kind of chronic disease, when you stop the treatment — in fact, whether you are taking an antihypertensive medication, when you abandon the treatment you gain a really high blood pressure,and we think that it’s the case of Acomplia Rimonabant”
Cluzel,also said on the advisory panel statement “My opinion is that the review committee took recognizance at this moment that obesity is a chronic disease, and I think that is the spirit of the comment’’.
Leave a Comment